NEUROCRINE BIOSCIENCES Business Summary

Neurocrine Biosciences (NBIX) is a commercial-stage biopharmaceutical leader that generates revenue primarily through the direct sale of proprietary therapeutics targeting neurological and endocrine-related disorders. Its financial engine is anchored by its flagship product, INGREZZA (valbenazine), the first FDA-approved treatment for tardive dyskinesia and chorea associated with Huntington’s disease, which accounted for approximately $2.51 billion of its $2.86 billion total revenue in 2025. The company’s growth strategy has recently pivoted toward diversification with the successful 2024 launch of CRENESSITY (crinecerfont) for congenital adrenal hyperplasia and an aggressive late-stage pipeline in neuropsychiatry, including osavampator for major depressive disorder and direclidine for schizophrenia. Within the competitive landscape, Neurocrine maintains a dominant position in the movement disorder market, competing directly with Biogen, Alnylam Pharmaceuticals, and Jazz Pharmaceuticals, while distinguishing itself through a specialized focus on VMAT2 inhibition and CRF antagonism. Leadership is currently spearheaded by CEO Kyle W. Gano, Ph.D., who assumed the role in October 2024 after a 23-year tenure at the company, most recently serving as Chief Business Development and Strategy Officer where he orchestrated key collaborations with AbbVie and Takeda. The executive suite includes CFO Matt Abernethy, formerly of Zimmer Biomet, and Chief Scientific Officer Jude Onyia, Ph.D., who brings deep R&D expertise from Eli Lilly. The company was co-founded in 1992 by the late Wylie Vale and former CEO Kevin Gorman, Ph.D., the latter of whom remains an influential member of the Board of Directors. Governance is further strengthened by Chairman William H. Rastetter, Ph.D., a veteran of Biogen Idec and Venrock, and board members such as Shalini Sharp and Johanna Mercier, ensuring a high level of institutional pedigree and strategic oversight as the firm transitions into a multi-product neuroscience powerhouse.